AI and Cell Therapy Intersect to Revolutionize the Biopharma Industry

 

Artificial intelligence (AI) is often associated with consumer-facing and mainstream industries such as gaming, securities and retail, but it plays just as crucial of a role in the biopharma industry. Sandi Colner, head of lab and life sciences vertical for Intel, and Stephanie Davies, head of science for cell therapy at ValitaCell, joined Host Tyler Kern to discuss this.

“The reason these therapies are important is that they really are a potential solution for a lot of diseases that don’t have alternative treatments like certain types of cancer, or OA and Crohn’s disease,” Davies explained.

Currently, the manufacturing process is still crude. This is partly because tools to monitor cell health and function can take half the time the entire process takes. Embedding a new breed of simple, automatable analytics in these processes — such as image and AI based assessment of cell quality — can help produce a high yield of quality cells to treat patients. This can help decrease the strenuous manufacturing processes that limit the industry.

Sandi Colner, head of Lab and Life Sciences at Intel says that the biopharmaceutical industry is undergoing an immense digital transformation driven by AI. “Although the application of AI in manufacturing is still in its nascent stage,” Colner says, “it’s already created an extensive ecosystem of different AI solution providers.”

Davies believes the key to accelerating this lies in industry collaboration. “I think these amazing collaborations that we are having across various parts of the industry are going to help connect different siloed data sets. It’s going to enable us to have access to sufficiently large data sets that are diverse and that are really going to be needed to train these AI models,” she said.

Looking to the future both Davies and Colner see many ways AI can help solve problems in the emerging cell and gene therapy industry. “This is difficult science, and we need to acknowledge that,” says Colner. She continues to explain that the next collaborations happening across various parts of the AI industry will enable new cell therapies to be delivered.

If you are interested in learning more or collaborating in the transformation of the biopharma industry, please connect with Stephanie Davies or Sandi Colner on LinkedIn.

Subscribe to the “Health and Life Sciences at the Edge” channel on Apple PodcastsSpotifyGoogle Podcasts, or Simplecast to hear more from the Intel Internet of Things Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

blue collar
Building Efficient and Engaged Blue-Collar Workforces Begins with Leadership Rooted in Personal Development
November 20, 2024

According to a study by Deloitte and The Manufacturing Institute, over 2.1 million manufacturing jobs could remain unfilled by 2030 due to a lack of skilled talent. This workforce shortage reveals a critical gap in leadership within blue-collar industries. Without strong leadership to develop teams and foster growth, businesses face inefficiencies, low morale, and…

Read More
Paying it Forward: Empowering Career Migration Journeys | Sinead Carbery and Gillian Williams | EP05
Paying it Forward: Empowering Career Migration Journeys
November 20, 2024

On the latest episode of Care Anywhere: The Global Health Workforce Podcast, host Lea Sims sits down with Sinead Carberry, President of International Staffing Solutions, and Gillian Williams, MSN, BS, RN, Senior Director of Clinical Operations, both from AMN Healthcare. The episode delves into the complexities of global career mobility for healthcare professionals, with…

Read More
Healthcare access
Improving Healthcare Access Through Nontraditional Benefits and Discount Plans
November 19, 2024

Healthcare costs are rising steadily, while insurance benefits struggle to offer sufficient coverage, driving demand for practical solutions like nontraditional benefits and discount plans. As premiums rise and coverage limits remain stagnant, many individuals and employers seek alternative ways to manage costs and improve healthcare access. With chronic conditions on the rise, the stakes…

Read More
CSR with Kelem Butts
Leading the Change in Corporate Social Responsibility with Kelem Butts: Tackling Health & Educational Challenges in a Disrupted World
November 19, 2024

In an era where corporate social responsibility (CSR) strategies are rapidly evolving, adapting to new challenges is paramount. As digital transformation accelerates societal shifts, organizations like United Way of Metropolitan Dallas are at the forefront of addressing critical issues, from education to economic mobility. This episode of DisruptED dives into the dynamic world of…

Read More